The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.

Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential ...

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, has entered into a ...

Lilly will use Rznomics’ proprietary ribozyme technology to develop RNA editing therapies for congenital hearing loss.

Eli Lilly is further expanding its RNA medicine strategy by tapping South Korea’s Rznomics for a $1.3 billion biobucks deal ...

Rznomics Inc., a South Korea-based biopharmaceutical company specializing in RNA-based therapeutics, announced today that it has entered into a strategic global research collaboration and licensing ...

Rznomics Inc. scored a potential ₩1.9 trillion (US$1.35 billion) global license option agreement with Eli Lilly and Co. to ...

Eli Lilly is building out its gene therapy pipeline for hearing loss through a new deal with RNA-focused startup Rznomics.

May 7, 2025 US judge sides with FDA's removal of Lilly's weight loss drug from shortage list A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

Co-development of precision RNA therapeutics for inherited hearing loss treatmentSEONGNAM, South Korea, May 15, 2025 /PRNewswire/ -- Rznomics Inc., a South Korea-based biopharmaceutical company ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP ...